CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PSORIASIS

被引:6
作者
Martin, B. [1 ]
Sanchez-Carazo, J. L. [1 ]
Perez-Ferriols, A. [1 ]
Laguna, C. [1 ]
Oliver, V. [1 ]
Alegre, V. [1 ]
机构
[1] Univ Valencia, Consorcio Hosp Gen, Serv Dermatol, Valencia, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2008年 / 99卷 / 07期
关键词
psoriasis; systemic therapy; biologic therapy; etanercept;
D O I
10.1016/S0001-7310(08)74739-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. Etanercept is one of the new biologic agents available for treating psoriasis. It has proved an effective option in a high percentage of patients, leading to sustained improvements in the psoriasis area severity index (PASI). Likewise, it is effective at controlling psoriatic arthritis, and its safety profile is excellent, with a much lower specific organ toxicity than traditional drugs and few side effects. Many of the data published to date are derived from clinical trials with this medication, but further studies are needed on the use of this therapy to manage patients in daily clinical practice. Methods. This was a retrospective observational study of 36 patients with psoriasis who received etanercept between March 2004 and March 2006. We describe the experience of using this agent at our hospital, with the clinical outcomes and the problems we have faced. Results. The PASI score was assessed before treatment and at 3 and 6 months of patient follow-up. After 3 months of treatment, 13 patients (36.11 %) had achieved a 50 % improvement in PASI score (PASI(50)), and 16 patients (44 %) had achieved a 75 % improvement (PASI(75)). Two of the patients (5.56 %) experienced an improvement in their disease without reaching PASI50 and only 4 patients (11.11 %) did not show clinical improvement or deteriorated. After 6 months, efficacy improved, with 27 patients (75 %) achieving PASI75, 6 patients (16.67 %) achieving PASI50, and 2 patients (5.56 %) showing no benefit from treatment. After 6 months, 13 of the patients (36.1 %) had achieved a 90% improvement in PASI score. No adverse events of sufficient significance to warrant discontinuation of treatment were reported. At present, 11 of the patients remain on etanercept treatment as efficacy has been sustained and they have not experienced any adverse events of note. Conclusions. Our clinical experience with the use of etanercept for treating plaque psoriasis shows a favorable efficacy and safety profile. We propose a standardized procedure for consultations with psoriasis patients involving extensive data collection on each visit and the creation of a national surveillance system for patients under treatment with biologic agents.
引用
收藏
页码:540 / 545
页数:6
相关论文
共 50 条
[31]   Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept [J].
Choi, Chong Won ;
Lee, Ji Su ;
Yu, Da-Ae ;
Kim, Bo Ri ;
Youn, Sang Woong .
ANNALS OF DERMATOLOGY, 2019, 31 (01) :44-50
[32]   A Clinical Trial of Combination Therapy with Etanercept and Low Dose Cyclosporine for the Treatment of Refractory Psoriasis [J].
Lee, Eun Ju ;
Shin, Min Kyung ;
Kim, Nack In .
ANNALS OF DERMATOLOGY, 2010, 22 (02) :138-142
[33]   CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE [J].
Esposito, M. ;
Giunta, A. ;
Mazzotta, A. ;
Babino, G. ;
Talamonti, M. ;
Chimenti, M. S. ;
Chimenti, S. .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (02) :503-509
[34]   Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment [J].
Puig, Lluis ;
Strohal, Robert ;
Fuiman, Joanne ;
Pedersen, Ronald ;
Szumski, Annette ;
Koenig, Andrew S. ;
Robertson, Deborah ;
Drexel, Heinz .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (06) :470-481
[35]   Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis [J].
Kivelevitch, Dario ;
Mansouri, Bobbak ;
Menter, Alan .
BIOLOGICS-TARGETS & THERAPY, 2014, 8 :169-182
[36]   Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis [J].
Park, Seung-Bae ;
Chang, In-Kyu ;
Im, Myung ;
Lee, Young ;
Kim, Chang-Deok ;
Seo, Young-Joon ;
Lee, Jeung-Hoon .
ANNALS OF DERMATOLOGY, 2015, 27 (05) :605-607
[37]   Leukemic Phase of Follicular Lymphoma after Treatment with Etanercept in a Patient with Psoriasis [J].
Siddhartha Ganguly .
American Journal of Clinical Dermatology, 2009, 10 :125-126
[38]   Etanercept in juvenile psoriasis [Etanercept in dertherapie der juvenilen psoriasis] [J].
Beikert F.C. ;
Augustin M. ;
Radtke M.A. .
Der Hautarzt, 2012, 63 (5) :406-410
[39]   Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients [J].
Zanni, Martina ;
Missale, Gabriele ;
Santilli, Daniele ;
Di Nuzzo, Sergio .
EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (04) :564-567
[40]   Effects of methotrexate and etanercept treatment in moderate and severe psoriasis [J].
Benites, Elizabeth ;
Carrillo, Esmeralda ;
Heras, Martha .
MEDICINE, 2022, 101 (45) :E31527